Applying Glycobiology To Develop Novel Medicines
About
IHP Therapeutics is applying Glycobiology to develop novel medicines. Glycobiology is an emerging field of research and drug development, with potential for treating multiple diseases.
IHP compounds are novel small molecule glycan therapeutics that inhibit selectin and complement activity. These compounds have the potential to (i) prevent immune response to AAV gene therapy and enabling AAV re-administration, (ii) rescue sickle cell disease patients in the prodromal phase of vasoocclusive crisis, (iii) treat other hematological diseases, such as hemolytic anemia, and (iv) inhibit cancer metastasis.
Mission
To pioneer the development of novel glyco-medicines
Our Team
Rinko Ghosh, MS, MBA
CEO
Jocelyn Jackson
Acting CFO
Peggy McLaughlin
VP of Clinical Operations
Gabriel Njikang, PhD
Director of CMC
John Paderi, PhD
Chief Science Officer
Kate Stuart, PhD
VP of Program Management
Robert Van Gorp
VP of Strategic Sourcing
Board of Directors
Rinko Ghosh, MS, MBA
Vlad Hogenhuis, MD, MBA
John Paderi, PhD
Clinical and Scientific Advisors
Science
IHP Therapeutics is building on nearly a century of clinical and basic science research with glycan-based compounds to create the next generation of glyco-medicines to treat diseases a broad spectrum of diseases, including those involving immune regulation and inflammatory processes.